; and (B) treat the references to schedule I in paragraph (3) as references to the appropriate schedule. (9) Definition In this subsection, the term legitimate research purposes has the meaning given to such term for purposes of subsection (a)(1). . (b) Transitional provisions (1) Current registrants Notwithstanding paragraph (1) of section 303(k) of the Controlled Substances Act, as added by subsection (a), any manufacturer that is registered under section 303(a) of the Controlled Substances Act ( 21 U.S.C. 823(a) ) to manufacture cannabis as of the date of enactment of this Act shall not be required to obtain a separate registration under such section 303(k) for the 1-year period following the date of enactment of this Act. (2) Pending applications Except as provided in paragraph (1), the Attorney General of the United States shall grant or deny, in accordance with section 303 of the Controlled Substances Act ( 21 U.S.C. 823 ), as amended by subsection (a), each application to manufacture cannabis to supply researchers in the United States that was submitted— (A) pursuant to the policy statement entitled Applications To Become Registered Under the Controlled Substances Act To Manufacture Marijuana To Supply Researchers in the United States published by the Drug Enforcement Administration in the Federal Register on August 12, 2016 (81 Fed. Reg. 53846); and (B) before the date of enactment of this Act. (c) Technical amendment Section 102(16) of the Controlled Substances Act ( 21 U.S.C. 802(16) ) is amended by inserting after The term marihuana the following: or marijuana or cannabis . 3. Provision by Department of Veterans Affairs health care providers of information regarding veteran participation in federally approved cannabis clinical trials (a) Provision of information and forms Notwithstanding any other provision of law, health care providers of the Department of Veterans Affairs may— (1) provide information to veterans regarding participation in federally approved cannabis clinical trials